A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. [electronic resource]
Producer: 20210909Description: 1145-1155 p. digitalISSN:- 1573-0646
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Checkpoint Kinase 1 -- antagonists & inhibitors
- Female
- Humans
- Imidazoles -- administration & dosage
- Male
- Middle Aged
- Models, Biological
- Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Pyrazines -- administration & dosage
- Pyrazoles -- administration & dosage
- Pyridines -- administration & dosage
- Treatment Outcome
- p38 Mitogen-Activated Protein Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.